Analysts at Stifel have adjusted their price target for Amazon.com Inc. (NASDAQ:AMZN) downward to $294 from $300, while maintaining a buy recommendation. The revised target remains well above the current share price of approximately $238.38.
Impact of Geopolitical Risks
Mark Kelley, a Stifel analyst, highlights rising energy costs from Middle East tensions, particularly Iran’s political instability, as a key concern. These factors prevented Amazon from meeting earnings consensus on April 11 and could further pressure marketplace margins through intensified cost structures.
Strong Growth Offsets Challenges
Despite these headwinds, Amazon demonstrates robust expansion in high-margin areas. AWS, advertising, and subscription services continue to drive significant revenue gains, positioning the company favorably amid broader market dynamics. Over the past 12 months, revenue grew 12.4%, supporting a market capitalization exceeding $2.56 trillion.
Amazon ranks as a top pick among retail investors, reflecting confidence in its operational strength.
Analyst Consensus Builds on AI Momentum
Several firms echo optimism around Amazon’s AI initiatives:
- Evercore ISI reaffirmed an Outperform rating with a $285 target, driven by AWS AI revenue projected to surpass $150 billion, accounting for about 10% of AWS totals. The AWS chip business exceeds expectations, with real growth nearing $200 billion.
- William Blair added Amazon to its Conviction List, citing CEO Andy Jassy’s recent shareholder letter. Jassy outlined aggressive AI infrastructure investments totaling $200 billion to capture substantial investor value.
- Truist Securities upheld a buy rating and $280 target, viewing AI commitments positively.
- Needham analyst Laura Martin maintained a buy but tempered capex enthusiasm, forecasting a $2,000 price target by 2026 based on earnings potential. Other hyperscalers pursue similar chip investments.
Expansion in Healthcare
Amazon Pharmacy bolsters its offerings by adding Foundayo, a GLP-1 weight-loss drug, to compete in the booming market. This move addresses rising demand and underscores Jassy’s emphasis on strategic participation in high-growth pharmaceuticals.
